868 results
Search Results
2. CHARACTERIZATION OF THE GENE ENCODING MOUSE PLATELET GLYCOPROTEIN Ibβ 1 1The nucleotide sequence data reported in this paper will appear in the DDBJ, EMBL and GenBank nucleotide sequence databases with the accession number AB001419
3. Studies on the mechanism of action of anti-inflammatory drugs. A paper in honour of John Vane
4. CHARACTERIZATION OF THE GENE ENCODING MOUSE PLATELET GLYCOPROTEIN Ibβ 1 1The nucleotide sequence data reported in this paper will appear in the DDBJ, EMBL and GenBank nucleotide sequence databases with the accession number AB001419.
5. Announcement and call for papers
6. CHARACTERIZATION OF THE GENE ENCODING MOUSE PLATELET GLYCOPROTEIN Ibβ11The nucleotide sequence data reported in this paper will appear in the DDBJ, EMBL and GenBank nucleotide sequence databases with the accession number AB001419.
7. The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs?
8. Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients
9. LMWH in cancer patients with renal impairment – better than warfarin?
10. Anticoagulants versus cancer
11. Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE): patterns of use and outcomes
12. Management of bleeding complications in patients with cancer on DOACs
13. Clinical practice guidelines on cancer-associated thrombosis: a review on scope and methodology
14. Management of recurrent venous thromboembolism in cancer patients
15. Long-term arterial complications of chemotherapy in patients with cancer
16. Primary prophylaxis of VTE in cancer outpatients
17. The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence – 15 Years and Counting
18. Predictors of recurrent venous thromboembolism and bleeding on anticoagulation
19. Risk of thrombosis in cancer and the role of supportive care (transfusion, catheters, and growth factors)
20. Clinical course of upper extremity deep vein thrombosis in patients with or without cancer: a systematic review
21. Update of thrombosis in multiple myeloma
22. Management of cancer-associated disseminated intravascular coagulation
23. Molecular biomarkers of thrombosis in myeloproliferative neoplasms
24. Intracranial hemorrhage in cancer patients treated with anticoagulation
25. Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study
26. Polymorphisms of the coagulation system and risk of cancer
27. Heparanase procoagulant activity in cancer progression
28. Biological basis of personalized anticoagulation in cancer: oncogene and oncomir networks as putative regulators of coagulopathy
29. Activated tumor cell integrin αvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream
30. Microparticles and cancer thrombosis in animal models
31. Incidental venous thromboembolic events in cancer patients: what we know in 2016
32. Cancer associated thrombosis: risk factors and outcomes
33. Venous thromboembolism and occult cancer: impact on clinical practice
34. Targeting clotting proteins in cancer therapy – progress and challenges
35. Standard measurement of clot-bound thrombin by using a chromogenic substrate for thrombin
36. Insights into platelet-based control of coagulation
37. Glycosaminoglycans in cancer treatment
38. Mechanistic explanation for platelet contribution to cancer metastasis
39. Potential antidotes for reversal of old and new oral anticoagulants
40. Cancer-associated unsuspected pulmonary embolism
41. Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants
42. Heparins and cancer survival: where do we stand?
43. Microenvironment and multiple myeloma spread
44. Guidelines for treatment and prevention of venous thromboembolism among patients with cancer
45. Complement the hemostatic system: an intimate relationship
46. New strategies of VTE prevention in cancer patients
47. Role of the protein C receptor in cancer progression
48. Thrombo-hemorrhagic deaths in acute promyelocytic leukemia
49. Abnormal adhesion of red blood cells in polycythemia vera: a prothrombotic effect?
50. Supportive transfusion therapy in cancer patients with acquired defects of hemostasis
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.